Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors

NCT06950697 is registered in ClinicalTrials.gov with Beijing Chao Yang Hospital as lead sponsor.

NCT NCT06950697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06950697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
Lead sponsor
Beijing Chao Yang Hospital
Phase
Observational
Overall status
Recruiting
Start date
January 1, 2019
Completion date
December 1, 2027
Enrollment
2,400 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

arterial thromboembolism, immune checkpoint inhibitors (icis), lung cancer, venous thromboembolism